Role of istradefylline for treating Parkinson’s disease

Abstract

This report evaluated the efficacy and safety of istradefylline in Parkinson’s disease patients with wearing-off symptoms and dyskinesia. Parkinson’s disease (PD) is the second-most common neurodegenerative disorder after Alzheimer’s disease. It slowly progressive neurodegenerative disease results from reduction of dopaminergic activity in nigrostriatal pathway. Istradefylline is non-dopaminergic, selective adenosine A2a receptor antagonist for the treatment of Parkinson’s disease (PD) in patients with wearing-off symptoms and dysknisia with levodopa (L-DOPA) therapy. Istradefylline safety was assessed by the incidence of treatment emergency adverse effects (TEAEs) and drug-related TEAEs. Effectiveness was assessed off-time, off-time symptoms, ON-time with dyskinesia and ON-time without dyskinesia. The change in daily OFF time duration was significantly reduced in the istradefylline 20 mg/day and istradefylline 40 mg/day groups. In the long term study that conducted in 2015 the most frequently TEAE was nasopharyngitis, and the most frequently drug-related TEAE was dyskinesia compared with the the study conducted between 2009 and 2011. istradefylline administered as adjunctive therapy to levodopa was safe and produced a sustained reduction in off time and further improved motor functions during on state in advanced Parkinson’s Disease (PD) patients